A Phase I Study of AG-348 in Healthy Volunteers

Healthy Volunteer Clinical Trial

— AG-348MAD  

Official title:

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of Orally Administered AG-348 in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02149966
• Other study ID #: AG348-C-002
• Status: Completed
• Phase: Phase 1
• First received: May 27, 2014
• Last updated: November 7, 2014
• Start date: May 2014
• Est. completion date: November 2014

Study information

• Verified date: November 2014
• Source: Agios Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a dose escalation study that will be conducted in healthy volunteers. Multiple cohorts of volunteers will receive ascending (increasingly higher) oral doses of AG-348 daily for 14 days to evaluate the safety and tolerability of multiple oral doses of AG-348, the pharmacokinetics (PK) of multiple doses of AG-348, and the pharmacodynamic profile of AG-348 with specific biomarkers assessed in the blood.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: November 2014
• Est. primary completion date: November 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Healthy adult male or female subjects 18 - 60 years, in good general health who are able to understand consent and complete all study procedures.

• Female subjects of non-child bearing potential (surgically sterile or post-menopausal as confirmed by age [over 50 years], amenorrhea for =12 consecutive months and FSH).

• Male subjects who are not vasectomized must agree to use contraception up to 30 days after dosing.

• Subjects with body weight =50 kg; BMI =18.5 and =32 kg/m2.

• Subjects who are non-smokers and have not used nicotine-containing products for at least 3 months prior to screening.

• Subjects must be willing to refrain from caffeine- or xanthene-containing products (coffee, tea, chocolate) for 48 hours prior to dosing through discharge from the clinical facility.

• Subjects must agree to refrain from strenuous exercise starting 72 hours prior to admission through final follow-up visit.

• Subjects must refrain from use of alcohol starting 7 days (14 days for red wine) prior to admission through final follow-up visit.

• Subjects must agree not to donate blood products for duration of study participation.

Exclusion Criteria:

• Subjects who have previously received AG-348.

• Subjects with clinically relevant screening laboratory tests.

• Female subjects who are not post-menopausal.

• Subjects with recent use of prescription, over the counter (OTC), herbal and/or dietary medications and/or supplements.

• Male subjects with QTcF interval ECG > 450 msec,or female subjects with QTcF interval ECG > 470 msec.

• Subjects with a history of a serious mental illness.

• Subjects with a clinically relevant medical history or pre-existing medical condition that would interfere with the absorption, metabolism or excretion of the study drug.

• Subjects with a history of any primary malignancy (cancer). Exceptions are certain skin cancers, cervical cancer in situ or other cancers that have been curatively treated without evidence of disease for a minimum of 1 year.

• Subjects with glucose-6-phosphate-dehydrogenase (G6PD) deficiency.

• Subjects who are positive for hepatitis B, hepatitis C or HIV.

• Subjects who have undergone surgery 6 months prior to screening.

• Subjects who have a history of illicit drug use or alcoholism within the last year.

• Subjects who are participating in other concurrent clinical trial of an investigational drug, or have received another investigational agent within the last 2 months.

• Subjects with any conditions which would make the subject unsuitable for enrollment, or could interfere with the subject's participation in or completion of the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Healthy Volunteer

Intervention

Drug:
• AG-348
A range of doses of AG-348 will be tested based on the assessment of safety and tolerability. AG-348 will be administered by mouth (orally) each day for a period of 14 days.
• Placebo
Placebo will be administered by mouth (orally) each day for a period of 14 days.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Agios Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse events		29 days	Yes
Secondary	Pharmacokinetics parameters of AG-348	Descriptive statistics will be used to summarize PK parameters of AG-348 for each dose group and, where appropriate, for the entire population. Standard non-compartmental PK parameters will be calculated from individual plasma concentration data.	17 days	Yes
Secondary	Pharmacodynamic (PD) relationship of AG-348 and metabolic biomarkers	The potential relationship between AG-348 and metabolic biomarkers will be explored with descriptive and graphical methods. Details on the evaluation of pyruvate kinase (PKR) activity and other potential PD biomarkers will be described.	17 days	No